{"entity":{"id":"adela-mced","kind":"drug","name":"Adela multi-cancer methylome test","aka":[],"tldr":"Adela's blood test in development for 20 cancer types, built on reading DNA methylation across the whole genome; no peer-reviewed screening results yet.","summary":"Adela, founded on cell-free methylated DNA immunoprecipitation work from Princess Margaret Cancer Centre, is developing a test for 20 pre-selected cancer types (company release, 26 May 2026) alongside its residual disease test. The CAMPERR case-control study (NCT05366881) is training and validating the platform across 20 cancer types. The only performance reported is a company conference figure: an interim AACR 2023 training readout across 12 cancer types with an area under the curve of 0.94 (0.92 at stage I), without sensitivity or specificity. No peer-reviewed multi-cancer paper, regulatory status or price was found.","status":"emerging","asOf":"2026-10-29","links":[{"label":"ClinicalTrials.gov NCT05366881","url":"https://clinicaltrials.gov/study/NCT05366881"},{"label":"Adela","url":"https://www.adelabio.com/"}],"tags":["test","mced","evidence:insufficient"],"related":[],"cancers":[],"sections":[],"technologies":["mced","liquid-biopsy","methylation-profiling","mrd-testing"],"targets":[],"drugs":[],"companies":["adela"],"institutions":["princess-margaret"],"pathways":[],"terms":[],"trials":["camperr"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Evidence grade insufficient for the claim that taking this test reduces late-stage diagnosis or cancer deaths: no randomised trial of it has reported either outcome, and its published performance comes from case-control or single-arm studies. The only randomised result for any multi-cancer test, NHS-Galleri, did not show fewer stage III or IV cancers.","What a result means: a positive result is a reason for further tests, not a diagnosis; a negative result does not rule cancer out and does not replace the screening tests that have been shown to work (bowel, breast, cervical and, where eligible, lung screening)."],"brand":"Adela","modality":"Multi-cancer early detection blood test in development (genome-wide methylome enrichment)","mechanism":"Enriches every methylated fragment of cell-free DNA without bisulphite conversion and classifies the genome-wide pattern, to detect cancer and tell cancer types apart.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/adela-mced/","neighbours":{"technology":[{"id":"methylation-profiling","kind":"technology","name":"DNA methylation profiling","route":"/technologies/methylation-profiling/"},{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"},{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/"},{"id":"mced","kind":"technology","name":"Multi-cancer early detection (MCED)","route":"/technologies/mced/"}],"company":[{"id":"adela","kind":"company","name":"Adela","route":"/companies/adela/"}],"institution":[{"id":"princess-margaret","kind":"institution","name":"Princess Margaret Cancer Centre","route":"/institutions/princess-margaret/"}],"trial":[{"id":"camperr","kind":"trial","name":"CAMPERR (Adela methylome test for early detection and residual disease)","route":"/trials/camperr/"}]}}